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This study aimed to describe health care provision, resource consumption and related costs, as
well as treatment patterns and quality of life in adult patients with pulmonary arterial hyper-
tension (PAH) in Germany.
Data for this retrospective and prospective cost-of-illness-study were derived from hospitals,
general practitioners and patients. Costs were evaluated from the perspective of third party
payer and patient. Quality of life data were collected by using three validated instruments.
A total of 167 patients were enrolled at 10 hospitals. Time period from first occurrence of
symptoms to confirmed diagnosis of PAH was 2.3 years on average. Mean number of GP visits
was 1.5 per patient per month, and within 15 months, inpatient stays were reported for 50%
of patients. The ratio of combination therapy to single-drug therapy for endothelin receptor
antagonists, phosphodiesterase-5-inhibitor and prostacyclin analogues increased significantly
during 15 months. Treatment costs were, on average, V47,400 per patient per year, arising
mainly from drugs. Compared to the general population, quality of life of PAH patients was
considerably impaired.
This is the first study which evaluated aspects of the medical and economic consequences of
PAH based on a large cohort of PAH patients in Germany.
ª 2010 Elsevier Ltd. All rights reserved.841 16 23619; fax: þ49 6841 16 23645.
uks.eu (H. Wilkens).
0 Elsevier Ltd. All rights reserved.
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Patients with pulmonary arterial hypertension (PAH) expe-
rience shortness of breath with effort, a limited exercise
capacity, edema and syncope and are threatened by
progressive right heart failure and premature death.1,2 The
quality of life (QOL) of PAH patients is considerably impair-
ed3e6 and mental disorders like anxiety and depression are
reported to be frequent.7,8
PAH consists of three main subgroups, idiopathic PAH,
familial PAH and PAH related to associated conditions e.g.
collagen vascular disease, congenital systemic-to-pulmonary
shunts, portal hypertension, HIV infection or exposure to
drugs and toxins.9,10 The disease is characterized by an
elevated mean pulmonary artery pressure 25 mmHg at rest
with a pulmonaryecapillary wedge pressure 15 mmHg
measured by cardiac catherization1,11 and is considered as
an orphan disease with a prevalence rate of 15e20 patients
per million adult inhabitants to 52 patients per million
population.12,13 Currently there is no cure for the disease,
however, new therapeutic approaches to PAH have been
developed within the last decade, aiming to reduce symp-
toms, to improve QOL, to slow disease progression and to
prolong life.14,15 Novel drug therapies include prostacyclin
analogues (PA), endothelin receptor antagonists (ER antag-
onists) and phosphodiesterase-5-inhibitors (PDE-5-inhibi-
tors), used as single agents or in combination.1,2,16
Information on clinical practice, the provision of medical
care under real-life conditions, as well as treatment costs of
PAH is very limited and data on QOL for German PAH patients
are not available.
In this study, data on disease specific characteristics of
PAH patients, health care provision, resource consumption
and associated costs, as well as data on patients’ QOL were
collected from a large cohort of PAH patients with the aim
of describing the medical and economic consequences of
PAH in Germany. The study considers symptoms and diag-
nostics until PAH diagnosis, in- and outpatient care, cost
from third party payers’ (sickness funds) and patients’
perspective. Additionally, the focus was on health-related
QOL and mental disorders.
Patients and methods
The study was conducted as a prospective and retro-
spective bottom-up cost-of-illness study, combined with
a prospective QOL study. Patients eligible for this study
had to be older than 17 years and diagnosed with PAH.
Data were collected 12 months retrospectively and 3
months prospectively. A subgroup of patients referred to
as ‘‘de novo patients’’ was diagnosed with PAH within the
last four weeks before inclusion in the study and could
participate only in the prospective part of the study. The
remaining patients had received medical care at the
study centre for a minimum of 12 months before enrol-
ment. Patients who participated in clinical studies were
excluded, except studies with duration of less than three
days. Patients were recruited by 9 university hospitals
and 1 comprehensive care centre for heart and lung
diseases. Ethic committees at each facility approved the
study protocol.Four different standardised questionnaires per patient
were used:
 One chart documentation form was used to abstract
data from patients’ charts regarding inpatient and
outpatient treatment in the study centre, e.g. diagnosis,
disease severity defined as New York Heart Association
(NYHA) functional classes IeIV,14 number of visits,
diagnostic procedures, hospitalisation, drug utilisation,
surgical procedures, etc. The observation period was 12
months retrospectively and 3 months prospectively; data
were documented per visit.
 One questionnaire to be completed by the general
practitioner (GP) responsible for primary care of the
PAH patient. The questionnaire covered retrospectively
symptoms, diagnostic procedures, referrals, rehabili-
tation measures, drug utilisation, sick leave, and early
retirement over a time period of 15 months; data were
documented cumulatively;
 Two patients’ questionnaires were used to gain infor-
mation about demographics and disease specific char-
acteristics, medical care (patients’ questionnaire A) and
patients’ expenditures over a time period of 3 months
(patients’ questionnaire B); resource consumption data
were reported cumulatively.
Data on patient’s QOL and mental disorders were
collected with three validated instruments which were
integrated in the patients’ questionnaires A and B: Euro-
pean Quality of life-5D (EQ-5D),17 Medical Outcomes Survey
36 Item Short Form health survey (SF-36) 18 and the Short
form of Patient Health Questionnaire (PHQ-D).19
Cost analysis
In the cost analyses, direct medical costs and direct non-
medical costs were evaluated from the perspective of third
party payer (TPP) and patient. Medications were multiplied
by the prices according to the German pharmaceutical
index ‘Rote Liste’20 or the ‘‘Arzneiverordnungsreport’’.21
Unit cost of office-based services and prices of physio-
therapy were calculated using the official German doctors’
fee scale titled ‘EBM 2000 plus’.22 Unit costs for hospital-
isations were based on case related allowances using
German diagnosis related groups (G-DRG; an average base
rate of V2,750 was used for calculation.).23,24 Official lists
of unit costs for outpatient visits and inpatient stays for
rehabilitation were unavailable and were therefore
obtained by telephone interviews with rehabilitation
centres. Direct non-medical costs from the patient
perspective (e.g. co-payments to medications, hospital-
isations etc., special home modifications like rebuilding)
were derived from the patients’ questionnaires.
QOL analysis
Health-related QOL and mental disorders were analysed at
enrolment and 3 months later.
The EQ-5D questionnaire consists of five scales
measuring the patients’ perception of their own current
health state including mobility, self-care, usual activities,
904 H. Wilkens et al.pain/discomfort, and anxiety/depression that produce
a single utility index score between 0 (death) and 1 (full
health).17 To calculate utility values, the health states
classification system created by Greiner et al. for Germany
was used.25
The SF-36 is designed to measure eight dimensions of
general, physical, and mental health, with scores ranging
from 0 to 100.18
For both the EQ-5D and the SF-36, higher scores indicate
better health-related QOL.
The short form of the Patient Health Questionnaire
(PHQ-D) covers mood and panic disorders.19 Patients indi-
cate whether, during the previous 2 weeks, the different
symptoms related to depression, fear and panic have
bothered them: 0Z not at all, 1Z several days, 2Zmore
than half of the days, or 3Z nearly every day. The
continuous variable is the sum of scores of the PHQ-D items
(range 0e27).
Statistical analysis
Data were analysed using SAS software (version 8.2) (SAS
Institute Inc., Cary, NC, USA). Frequency distributions of
study parameters as well as mean, median, standard devi-
ation (SD), minimum and maximum were calculated. QOL
parameters were analysed according to questionnaire
specific algorithms. For testing of the QOL values at two
observational time points, the following statistical tests
were used: Wilcoxon test (EQ-5D, SF-36 questionnaires),
McNemar test,26 sign test (PHQ-D).Figure 1 Disposition of patienResults
One hundred and sixty seven (nZ 167) patients treated
between 10/2004 and 12/2006 were enrolled in the study
(Fig. 1); 156 patients had a minimum of 12 months estab-
lished PAH diagnosis (93%) and 11 were ‘‘de novo patients’’
(7%). The response rate from general practitioners was 49%
(nZ 81); 89% of patients (nZ 148) filled in questionnaire A,
and after 3 months 74% (nZ 124) completed questionnaire
B (mean time: 3.3 0.8 months). Chart documentation and
all three questionnaires were completed for 63 patients.
Patients experienced on average already as long as 2.3
years (SD 3.7) symptoms of PAH before the diagnosis was
established. Over 50% of patients (54%) consulted three or
more physicians before they received the final diagnosis of
PAH. In 35% of the patients the first diagnosis of PAH was
made by a cardiologist, in 47% by a pneumologist, and in 5%
by an internist. The most frequent symptoms related to PAH
which led patients to see their doctor were dyspnoea
caused by exertion (91%), chronic fatigue (66%) and tired-
ness (48%). During evaluation for PAH diagnosis the most
frequent diagnostic procedures that were documented
were echocardiography (87% of patients), electrocardio-
gram (87% of patients) lung function test (87% of patients)
and right heart catheterisation (76% of patients). For three
patients who received right heart catheterisation, no
echocardiography was documented.
The baseline characteristics of the patients are shown in
Table 1. The mean age was 55.6 years (minimum 19 years,
maximum 86 years) and the majority of patients had PAHts (TPP: third party payer).
Table 1 Characteristics of the patient population.
Subjects n 142
Female/male 103/39 (73/27)
Age yrs 55.6 14.3
Time period since PAH diagnosis yrs 5.4 5.8
Type of PAH
IPAH 88 (62)
PAH 50 (35)
Not reported 4 (3)
PAH associated diseases 50(35)
Collagen vascular diseases 19 (38)
Congenital systemic-to-
pulmonary shunts
15 (30)
Portal hypertension 10 (20)
Other diseases 6 (12)
Disease severity at time point of enrolment
NYHA I 2 (1)
NYHA II 46 (32)
NYHA III 68 (48)
NYHA IV 9 (6)
Not available 17 (12)
6-min walk test in m 386 129
Concomitant
Cardiovascular disorders 53 (37)
Metabolic disorders 30 (21)
Respiratory disorders 30 (21)
Liver & gall bladder disorders 9 (6)
Kidney disorders 7 (5)
Autoimmune disorders 5 (4)
Others 25 (18)
Employment status
Employed or freelance 21 (14.8)
At home 15 (10.6)
Not working because of PAH 15 (10.6)
Unemployed 1 (0.7)
Early retired because of PAH 30 (21.1)
Early retired because of other reasons 10 (7.0)
Retired 38 (26.8)
Not available 12 (8.5)
Data are presented as n (%) or mean SD. IPAH: idiopathic
pulmonary arterial hypertension; NYHA I to IV: New York Heart
Association functional classes; Class I: no limitation in physical
activity; Class II: slight limitation in physical activity; Class III:
marked limitation of physical activity; Class IV: unable to
perform any physical activity without symptoms.14
Table 2 Resource consumption during a 15 months
observation period.
Subjects n from
chart abstraction
130
Outpatient visits
at hospitals
125 (96)
Number of outpatient
visits per patient
5.1 3.4
Inpatient stays 66 (50)
Length of stay in days 11.8 28.2
Diagnostic procedures Outpatient
visits
Inpatient
stays
Total 564 (100) 112 (100)
Laboratory tests 564 (100) 112 (100)
Lung function testing 505 (90) 75 (67)
Electrocardiogram 369 (65) 81 (72)
Chest X-ray 238 (42) 38 (34)
Echocardiography 228 (40) 73 (65)
Spiroergometry 60 (11) 17 (15)
Right heart
catheterisation
5 (1) 43 (38)
Computed tomography
thorax
7 (1) 18 (16)
Spiral computed
tomography thorax
2 (< 1) 9 (8)
Ventilation perfusion
scintigraphy
1 (< 1) 5 (5)
Pulmonary angiography 0 3 (3)
Data are presented as n (%) or mean SD.
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were documented for 64% of patients. Approximately 55%
of PAH patients held a severely handicapped ID card
because of PAH. Personal support received 73% of the
patients, 57% by the partner and 43% by other family
members. Eight percent (8%) of patients were supported by
patient organisations.
Resource utilisation
Details of resource consumption over a 15 month time period
evaluated by chart abstraction are given in Table 2. Meannumber of GP visits were 22.6 (SD 16.0) and of visits at
outpatient departments 5.1 (SD 3.4) per patient. About
44% of GP visits and 91% of visits at outpatient departments
were follow-up visits. Surgical procedures like port implan-
tation or replacement were performed in 7% of inpatient
stays. Data from outpatient visits revealed, in addition, that
91% of patients were referred to specialists during the 15
months observation period: 52% to PH centres, 28% to
pneumologists at hospitals, and 20% to office-based cardi-
ologists. About 10% of patients received a rehabilitation
measure within 15 months with a mean duration of 30.1 days
(SD 11.3 days). General treatment measures included oral
anticoagulants (61%), diuretics (62%), Ca-channel blockers
(27%), mobile oxygen (24%), digitalis (8%) and antidepres-
sants (4%).
Data on PAH specific therapy with ER antagonists, PDE-5-
inhibitor and PA are presented in Table 3. The most
frequently used single-drug therapy was ER antagonist (47%
of patients), the most frequently used combination therapy
was ER antagonist plus PDE-5-inhibitor (21% of patients).
There is a statistically significant difference between the
ratio of single-drug therapy to combination therapy at the
first documented outpatient visit compared to the last
documented outpatient visit over a 15 month time period
(McNemar test, p< 0.0001). At the beginning of the
observation period approximately 9% of patients received
no specific drug therapy with ER antagonists, PDE-5-inhib-
itor or PA. At the last documented visit all patients received
at least one of the aforementioned drugs.
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Costs were looked at from the perspective of the TPP,
calculated for a time period of 12 months and the patient,
evaluated for a three month time period as outlined in detail
in Table 4. Overall, mean direct costs related to PAH were
V47,424 per patient, per year, including drug treatment,
outpatient visits and hospitalisation. Stratified by disease
severity, direct costs were V41,134 (SD 51,142; NYHA II),
V50,281 (SD 55,350; NYHA III) and V52,332 (SD 41,162;
NYHA IV) per patient, per year. Costs varied over a wide
range from V52 to V351,775 per patient, per year. This
maximum treatment cost refers to patients receiving PA
intravenously. From the patient perspective, home modifi-
cations, like rebuilding, accounted for the highest costs.
Total costs per patient from the TPP and the patient
perspective extrapolated for one year was approximately
V50,000.
Quality of life and mental disorders
The instruments used for assessment of the different QOL
dimensions revealed decreased QOL of the PAH patients
at the time point of enrolment as well as three months
later as shown in Table 5. No statistically significant
changes after three months compared to enrolment
could be observed in the data of all three instruments
applied. In NYHA class IV, the EQ-5D utility index score
fell from 0.54 (SD 0.06) to 0.39 (SD 0.38) over the
three months observation period. However, only 6Table 3 Single-drug therapy and combination therapy over a 1
F
v
w
Subjects n with data at both time points 1
No therapy with ER antagonist, PDE-5-inhibitor or PA 1
Single-drug therapy 7
ER antagonist 5
PDE-5-inhibitor 1
PA (inhaled) 8
PA (oral) 1
Combination therapy 3
ER antagonistþ PDE-5-inhibitor 1
PA (inhaled)þ ER antagonist 1
PA (inhaled)þ PDE-5-inhibitor 3
PA (inhaled)þ ER antagonistþ PDE-5-inhibitor 3
PA (oral)þ ER antagonistþ PDE-5-inhibitor 3
PA (oral)þ ER antagonist 0
PA (oral)þ PDE-5-inhibitor 0
PA (i.v.)þ ER antagonistþ PDE-5-inhibitor 1
PA (i.v.)þ ER antagonist 1
PA (i.v.)þ PDE-5-inhibitor 1
PA (i.v.)þ PA (inhaled)þ ER antagonist 0
PA (i.v.)þ PA (inhaled)þ ER antagonistþ PDE-5-inhibitor 0
Data are presented as n (%). PDE-5-inhibitor: phosphodiesteras
PA: Prostacyclin analogue; i.v.: intravenous.
a Last vs. first visit, p< 0.0001.patients classified as NYHA IV answered the questionnaire
at both time points. At the time of enrolment, about 11%
of patients had minor depressions and 13% experienced
panic attacks.
Looking at the SF-36 scores stratified by disease severity
the NYHA class III and IV patients showed lowered scores for
the dimensions physical functioning, role-physical, general
health and vitality compared to NYHA class II patients,
however, these differences were not statistically significant
(Fig. 2).
Discussion
Our study showed that the mean time period between the
first onset of symptoms to confirmed diagnosis of PAH was
still 2.3 years (SD 3.7). This concurs with data from
a French registry for PAH conducted with patients seen
between 10/2002 and 10/2003 reporting also an average of
2.3 years (27 months).12 Consistently, the number of
patients with NYHA I in our sample was relatively small,
again in agreement with the rate of diagnosis in NYHA I
patients in the literature.12,13,28 In conclusion early diag-
nosis of PAH remains difficult. Once diagnosed, however,
the PAH patients in this study were closely followed up
considering the high number of outpatient visits and inpa-
tient stays, as well as the large array of diagnostic proce-
dures used. The impact of outpatient visits on overall
treatment cost was small (about V750 per patient and
year). Generally, a close follow-up may have a positive
impact on third party payer cost.5 months time period.
irst documented outpatient
isit at the hospital
ithin 15 months
Last documented outpatient
visit at the hospital
within 15 months
18
0 (9) 0 (0)
6 (64) 67 (57)a
5 (47) 43 (36)
2 (10) 18 (15)
(7) 6 (5)
(1) 0 (0)
2 (27) 51 (43)a
0 (9) 25 (21)
0 (9) 6 (5)
(3) 4 (3)
(3) 5 (4)
(3) 3 (3)
(0) 1 (1)
(0) 1 (1)
(1) 1(1)
(1) 1 (1)
(1) 1 (1)
(0) 1 (1)
(0) 2 (2)
e-5-inhibitor; ER antagonist: endothelin receptor antagonist;
Table 4 Costs per patient from third party payers’ (TPP) and patient perspective.
Mean SD Median Minimum Maximum
Direct costs per patient from TPP perspective, data derived from patients’ charts: time period 12 months, subjects nZ 130.
Drugs 45,634 51,843 43,302 0 349,150
Outpatient visits at hospital 267 178 260 0 1144
Inpatient stay 1,523 3,427 2,365 0 37,371
Total 47,424 52,289 44,578 52 351,775
Direct costs per patient from TPP perspective, data derived from general practitioner questionnaire: time period 12 months,
subjects nZ 78.
Rehabilitation 255 810 0 0 3,797
Office-based physician visits 487 328 368 48 1,565
Total 742 917 429 48 5,032
Direct costs per patient from the patient perspective, data derived from patient questionnaire: time period 3 months,
subjects nZ 110.
Co-payment
Office-based physician 16 47 0 0 348
Drugs 38 52 17 0 260
Hospital stay 8 36 0 0 269
Physiotherapist 3 12 0 0 74
Other costs
OTC drugs 9 23 0 0 130
Domestic devices 8 19 0 0 105
Household 48 185 0 0 1,200
Home modifications 340 2,117 0 0 16,000
Total 470 2,193 60 0 16,430
Data are presented in V. For the costs per patient from the TPP perspective an equal distribution over the 12 months period was
assumed. OTC drugs: over the counter drugs.
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colleagues 95% of 123 PAH patients started on a single-
drug therapy, 43.2% had to switch to a two-drug regimen
and 16.1% to a triple-drug regimen to achieve measurable
stabilisation of the disease. 4.2% of the patients were on
intravenous PA. One patient required lung trans-
plantation.16 In our study 64% of 118 patients received
a single-drug therapy at their first documented outpatient
visit at the hospital, 19% a two-drug therapy, 5% a triple-
drug therapy and 2.5% intravenous PA. None of our
patients required lung transplantation. At the last docu-
mented outpatient visit at the hospital within 15 months
we documented an increase to 31% of the patients on
two-drug therapy, 7% on triple-drug therapy and 5% on
intravenous PA, whereas 57% remained on single-drug
therapy. The higher percentages of patients in the
different therapy groups in the Hoeper-study compared to
our results are probably explained by a larger proportion
of NYHA class III and IV patients in this study (80%/20%
compared to only 48%/6% in our study). The trend to
use multiple specific drugs was also observed in the
Swiss registry.28
Generally, an improvement of survival of PAH patients,
a decline in treatment with intravenous PA and in the rate
of lung transplantation could be achieved by the intro-
duction of new pharmaceutical agents and the increase in
combination therapies.15,16 An alignment of special
combination therapies to NYHA classes was not possible in
our study, which might reflect that treatment decisionsfor these seriously ill patients are made on an individual
basis.
Already a single-drug specific therapy for PAH can be
very costly, which explains the broad variation of costs for
single patients. As expected, direct medical costs increased
with increasing severity level. In the literature, data on
costs for PAH are scarce and refer to comparison of
different therapies for PAH. Highland and colleagues con-
ducted a costeeffectiveness comparison of an ER antago-
nist with two different prostacyclin analogues. Reported
direct medical costs for 2002 in the USA were $36,208,
$89,038 and $73,790 (V28,589; V70,302; V58,263; Feb. 19,
2009) for therapy with Bosentan, Treprostinil and Epo-
prostenol respectively for one year.29
The economic burden of PAH patients is considerable.
Co-payments e.g. to medications, hospitalisations etc. and
other expenses associated with PAH were, on average,
V1880 per patient, per year. This is a significant economic
burden for patients and families, considering that the vast
majority of the patients were retired or not employed.
About 32% of patients were retired or not employed
because of PAH. Facing the fact, that in our society a great
importance is attached to work in terms, the disability to
work has an additional negative effect on PAH patients and
their families. Also it has a substantial economic impact for
the society due to productivity losses.
During the last five years several studies on QOL of PAH
patients have been published,3e6,8 mostly in the USA, with
a recent review of QOL in 2008.30 In a non-curable disease
Table 5 Quality of life and mental disorders at the time of enrolment (A) and three months later (B).
EQ-5D Utility index scores from 0 to 1 (mean SD)
NYHA functional classes Subjects n A B
Total 95 0.62 0.16 0.61 0.21
NYHA II 30 0.73 0.16 0.69 0.14
NYHA III 44 0.55 0.20 0.55 0.21
NYHA IV 6 0.54 0.06 0.39 0.38
SF-36 Scores from 0 to 100 (mean SD)
Dimensions Subjects n A B
Physical functioning 116 38.9 24.6 36.9 23.5
Role-physical 96 40.4 43.8 33.3 39.9
Bodily pain 109 67.0 29.1 66.2 28.8
General health 111 41.2 17.9 41.2 17.9
Vitality 116 42.5 19.0 41.7 18.8
Social functioning 114 64.7 27.5 64.7 25.5
Role-emotional 91 72.5 41.8 65.8 43.9
Mental health 113 63.5 17.8 63.4 18.9
PHQ-D Subjects n (%)
Mood and panic disorders Subjects n A B
Depression major 118 8 (7) 9 (8)
Depression major or minor 118 21 (18) 17 (14)
Panic attacks 102 13 (13) 12 (12)
Impact of problems on daily life: 110
Not difficult at all 16 (15) 14 (13)
Somewhat difficult 62 (56) 68 (62)
Very difficult 21 (19) 20 (18)
Extremely difficult 11 (10) 8 (7)
EQ-5D: European quality of life-5D; SF-36: medical outcomes survey 36 item short form health survey; PHQ-D: short form of patient
health questionnaire. NYHA II to IV: New York Heart Association functional classes. Only data from patients who filled in the specific part
of the questionnaire at both time points are shown (subjects n).
908 H. Wilkens et al.like PAH the therapeutic aim is not only to prolong life, but
also to improve QOL, or at least to prevent a deterioration
of QOL in the seriously ill patients. As expected, health-
related QOL of PAH patients measured by EQ-5D and SF-36
questionnaires was remarkably reduced, especially in NYHA
functional class III and IV patients (utility index scores of
EQ-5D) and in the physical functioning, role-physical,
general health and vitality dimensions of SF-36. Presented
utility index score corresponds well to results of an UK
study in pH patients (NYHA II: 0.69; NYHA III: 0.57; NYHA IV:
0.43).31 Two US studies conducted in 155 and 93 patients
with similar characteristics found as in our study a reduc-
tion predominantly in the physical functioning, role-phys-
ical, general health dimensions, but also in the role-
emotional dimension of SF-36.5,6 In our study a consider-
able percentage of PAH patients suffered from panic
attacks and depression as documented with the specific
questionnaire PHQ-D asking for mood and panic disorders.
The complexity of disturbances in QOL of patients with the
chronic disease PAH was only captured by using different
questionnaires in our study. Another possibility is the use of
questionnaires adapted to the disease specific problems,
recently available also for PAH in English speaking
countries.6
The impact of the high number GP visits on QOL cannot be
clearly demonstrated in the presented study, because data
on QOL were obtained for a 3-month-period and reported
number of GP visits refers to a time period of 15 months.There are some limitations to this study. First, the study
sample was dominated by patients in NYHA classes II and III
and therefore cannot be generalised to patients in NYHA
class I and IV. Secondly, the results of this study refer to
patients who received most of their medical care in spe-
cialised centres, qualified for and experienced in the
treatment of PAH patients. Therefore, resource consump-
tion (visits, diagnostic procedures, drug utilisation) could
be indicating an upper range of resource use and a gener-
alisation of these results to all PAH patients in Germany
might not be true. Also it has to be taken into consideration
that the occurrence of concomitant diseases, especially
cardiovascular or respiratory diseases, may have led to an
overestimation of costs, because it could not in all cases
clearly distinguish between a resource use related to PAH or
to the concomitant diseases. Thirdly, a selection bias
cannot be discounted, since preferentially, patients might
have been asked for participation in the study, which were
thought to be compliant and healthy enough to complete
the questionnaires. This possible selection bias however,
does not explain the high response rate of general practi-
tioners, indicating that the aims of the study were of
special interest to both patients and physicians. Although
the response rate of GPs is relatively high, about 50% of
them did not answer the questionnaire. This may have lead
to an under- or overestimation of resource use and associ-
ated cost. Also a recall bias may have affected the resource
use reported by the patients because they have had to
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Figure 2 Dimensions of medical outcomes survey 36 item short form health survey (SF-36): PAH patients stratified by New York
Heart Association (NYHA) functional classes IIeIV compared to general population in Germany (50e59 years, female).27 Data were
obtained at the time of enrolment and are presented as mean values of transformed scale scores. Note that for the dimension
role-physical the NYHA functional class IV patients indicated on average the value zero.
Pulmonary arterial hypertension in Germany 909remember co-payments and expenses over a time period of
3 months retrospectively. However, for chronically ill
patients it can be expected that they remember their
expenses more correctly than patients with an acute
disorder. Overall, the impact on total cost can be neglec-
ted, because the main part of total cost was obtained from
chart abstraction data.
In conclusion, this is the first comprehensive data
collection from a large cohort of PAH patients in Germany
showing the burden of this rare disease from a medical,
economic and patient perspective. Our results might serve as
a basis for further optimising management and living
conditions of PAH patients. They emphasise also the impor-
tance of an increasing awareness of this disease, to expedite
the process of a correct diagnosis and the referral of PAH
patients to specialised centres.
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